NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Not likely. That is not how acquisitions work for large companies. A direct competitor might want to see the company struggle and to take its IP. But a large drug company that may be seeking a later relationship, either partnership or acquisition wants to see the product validated before they acquire any interest in it. They are risk averse. They have plenty of income and resources, they are looking for products that they can transform into gold, and an early acquisition doesn’t suit them if it is not validated yet. But once validated, then it is something that they can calculate the value for if they own it and use it for instance as a way to create a stronger product line and combination therapy route in Oncology, it can create a dominance that lasts for decades.